Linking Insights for Multiple Myeloma Patient Care
Unite for MM: Linking Insights for MM Patient Care
Watch Dr Rakesh Popat highlight the Unite for MM initiative
With the availability of immunotherapies, such as bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T-cell therapies, patients and health care professionals (HCPs) now have more options to treat relapsed/refractory multiple myeloma (RRMM) than ever before.1-3 However, navigating this complex landscape remains challenging due to limited insights into perspectives on treatment decision-making by patients and HCPs.1
Together with Pfizer, a multinational Steering Committee composed of members across the multiple myeloma (MM) community developed the first large-scale survey of its kind to better understand RRMM care.1
This site shares the survey findings and offers considerations to help improve MM care.
Key gaps and unmet needs for the adoption of immunotherapies that may impact patient care1
Explore the Unite for MM website to discover survey insights and what they may mean for you
References
- Ailawadhi S, Biru Y, Clavreul S, et al. Perspectives of healthcare providers and patients with relapsed/refractory multiple myeloma on treatment priorities and novel therapies. Patient Prefer Adherence. 2025;19:1089-1104. Published April 2, 2025. Taylor & Francis Ltd. Reprinted by permission of the publisher Informa UK Limited trading as Taylor & Francis Ltd, http://www.tandfonline.com.
- Banerjee R, Biru Y, Cole CE, Faiman B, Midha S, Ailawadhi S. Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel. Blood Cancer J. 2024;14(1):149.
- Nishida H. Rapid progress in immunotherapies for multiple myeloma: an updated comprehensive review. Cancers (Basel). 2021;13(11):2712.